Astellas Drops Alzheimer’s Compound After Phase II Interim Analysis
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese firm will discontinue FK962 after data did not indicate clear efficacy for the treatment of Alzheimer’s disease.